Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Benitec Biopharma (BNTC) to $29 from $35 and keeps an Outperform rating on the shares. Since the last corporate update in July, Benitec remains on track to present full data from the Phase 1b/2a clinical study of lead candidate BB-301 in OPMD in October including all six patients in Cohort 1. Based on durable and clinically meaningful improvements in dysphagia seen in the twelve-month data from Cohort 1 presented at the 2025 MDA conference in March, Oppenheimer expects to see continued benefit. Importantly, these data help to inform regulatory discussions whereby Benitec could advance to a registrational trial with a limited number of additional patients at the current dose based on precedent set by other rare disease companies. The firm continues to view Benitec’s “silence and replace” DNA-directed RNA interference platform as differentiated, disease-modifying approach to treating OPMD.